147 related articles for article (PubMed ID: 32879437)
1. Registration pathways to accelerate regulatory assessment of innovative medicines in Latin America.
Padua A; Partika L; Bonamici D; Rahal Cabello J; Kohiyama C; Spinardi P; Castro A; Rolim A; Souto F
J Public Health Policy; 2020 Dec; 41(4):481-495. PubMed ID: 32879437
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications.
Argotti U; Leyens L; Lisbona C; López P; Alonso-Orgaz S; Nevado A; Cozzi V
Ther Innov Regul Sci; 2023 Nov; 57(6):1287-1297. PubMed ID: 37682461
[TBL] [Abstract][Full Text] [Related]
3. Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice.
Rodier C; Bujar M; McAuslane N; Patel P; Liberti L
Ther Innov Regul Sci; 2021 Jan; 55(1):118-128. PubMed ID: 32617911
[TBL] [Abstract][Full Text] [Related]
4. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action?
Vaz A; Roldão Santos M; Gwaza L; Mezquita González E; Pajewska Lewandowska M; Azatyan S; Saint-Raymond A
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):11-17. PubMed ID: 35130803
[TBL] [Abstract][Full Text] [Related]
5. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
[TBL] [Abstract][Full Text] [Related]
6. Strengthening vaccination policies in Latin America: an evidence-based approach.
Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Rivera VM
Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
[TBL] [Abstract][Full Text] [Related]
8. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth report.
World Health Organ Tech Rep Ser; 2016; (996):1-358, back cover. PubMed ID: 27514184
[TBL] [Abstract][Full Text] [Related]
9. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
[TBL] [Abstract][Full Text] [Related]
11. [Alternatives for adopting policies centered on access to medicines].
Tobar F; Drake I; Martich E
Rev Panam Salud Publica; 2012 Dec; 32(6):457-63. PubMed ID: 23370190
[TBL] [Abstract][Full Text] [Related]
12. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
[No Abstract] [Full Text] [Related]
13. A Proposal of a Combined Convergence Regulatory Strategy Applied to Post-approval Changes by Latin American Countries, Reducing Workload and Allowing Continuous Improvement to Guarantee the Quality, Safety, and Efficacy of Medicines.
Rodriguez H; De Lucia ML
Front Med (Lausanne); 2021; 8():768376. PubMed ID: 34888329
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. WHO expert committee on specifications for pharmaceutical preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2013; (981):i-xi, 1-188. PubMed ID: 23821930
[TBL] [Abstract][Full Text] [Related]
16. Relevance of variation in use of terminology to define generic pharmaceutical products.
Fonseca EM
Rev Panam Salud Publica; 2015 Feb; 37(2):113-7. PubMed ID: 25915016
[TBL] [Abstract][Full Text] [Related]
17. Follow-on products for treatment of multiple sclerosis in Latin America: An update.
Correale J
J Neurol Sci; 2017 Oct; 381():153-159. PubMed ID: 28991670
[TBL] [Abstract][Full Text] [Related]
18. Reliance: a smarter way of regulating medical products - The IPRP survey.
Doerr P; Valentin M; Nakashima N; Orphanos N; Santos G; Balkamos G; Saint-Raymond A
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):173-177. PubMed ID: 33355025
[No Abstract] [Full Text] [Related]
19. Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities.
McAuslane N; Bujar M; Sithole T; Ngum N; Owusu-Asante M; Walker S
Pharmaceut Med; 2023 May; 37(3):251-260. PubMed ID: 37074548
[TBL] [Abstract][Full Text] [Related]
20. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2011; (961):1-428, back cover. PubMed ID: 21699061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
